Literature DB >> 14647793

[Visceral leishmaniasis: clinical and laboratorial aspects].

Antonio C Pastorino1, Cristina M A Jacob, Gabriel W Oselka, Magda M S Carneiro-Sampaio.   

Abstract

OBJECTIVE: To compare the clinical and laboratorial data before and after the treatment of patients with visceral leishmaniasis admitted to a pediatric hospital in a nonendemic area, highlighting the importance of recognizing visceral leishmaniasis in pediatric patients.
METHODS: Clinical, laboratorial and treatment data of 78 patients with visceral leishmaniasis were evaluated from 1981 to 1992. We analyzed the average level of hemoglobin, leukocyte, neutrophil, platelet, albumin, gammaglobulin, class and subclass of immunoglobulin, size of the liver and spleen during the pre- and post-treatment using the paired t test.
RESULTS: We included 78 patients with visceral leishmaniasis, 44 males, with age ranging from 8 months to 13.5 years. Sixty-one patients were from Bahia. Fever and splenomegaly were present in 96.1% and 100% of the cases, respectively. The parasitological diagnosis was obtained in 74/78 patients: 67 patients through smear and/or culture of bone marrow (85.7%), five through liver biopsy and two through spleen puncture. The hematological findings and serum albumin presented significant improvement at the end of treatment (P<0.001), differently from serum gammaglobulin levels (P=0.087). There was predominance of IgG1 subclass, with two patients presenting low levels of IgG2. Initial treatment used antimoniate in 67 cases and amphotericin B in five. Eleven patients (15.7%) needed a second treatment, and were considered cured after it. There was significant improvement in the liver and spleen size at the end of the treatment (P<0.001). One patient presented spontaneous remission and five died due to bleeding.
CONCLUSIONS: In order to obtain accurate diagnosis and treatment, especially regarding health services of areas with low-incidence of visceral leishmaniasis, the diagnosis of patients with fever and visceromegaly, who come from endemic areas, should include visceral leishmaniasis.

Entities:  

Year:  2002        PMID: 14647793

Source DB:  PubMed          Journal:  J Pediatr (Rio J)        ISSN: 0021-7557            Impact factor:   2.197


  7 in total

1.  DNA vaccination with KMP11 and Lutzomyia longipalpis salivary protein protects hamsters against visceral leishmaniasis.

Authors:  Robson A A da Silva; Natália M Tavares; Dirceu Costa; Maiana Pitombo; Larissa Barbosa; Kyioshi Fukutani; Jose C Miranda; Camila I de Oliveira; Jesus G Valenzuela; Aldina Barral; Manuel Soto; Manoel Barral-Netto; Cláudia Brodskyn
Journal:  Acta Trop       Date:  2011-08-22       Impact factor: 3.112

2.  Clinical characteristics and spatial distribution of Visceral leishmaniasis in children in São Paulo state: an emerging focus of Visceral leishmaniasis in Brazil.

Authors:  Patricia Rodrigues Naufal Spir; Luiz Euribel Prestes-Carneiro; Elivelton Silva Fonseca; Aline Dayse; Rogério Giuffrida; Lourdes Aparecida Zampieri D'Andrea
Journal:  Pathog Glob Health       Date:  2017-02-21       Impact factor: 2.894

3.  Late diagnosis: a factor associated with death from visceral leishmaniasis in elderly patients.

Authors:  Marta Driemeier; Polliana Alvarenga de Oliveira; Angelita Fernandes Druzian; Laís Ferreira Lopes Brum; Elenir Rose Jardim Cury Pontes; Maria Elizabeth Cavalheiros Dorval; Anamaria Mello Miranda Paniago
Journal:  Pathog Glob Health       Date:  2015-08-10       Impact factor: 2.894

4.  Does Leishmaniasis disease alter the parenchyma and protein expression in salivary glands?

Authors:  Aírton M C Júnior; Fernando A de Amorim Carvalho; Weslany de Oliveira Dantas; Luana C L Gomes; Andrezza B S da Silva; Maria M A de Sousa Cavalcante; Ingrid M de Oliveira; Marina de Deus Moura de Lima; Márcia Dos Santos Rizzo; Carla Maria de Carvalho Leite; Selma Maria Dos Santos Moura; Lúcia de Fátima Almeida de Deus Moura; Benedito B da Silva
Journal:  Exp Biol Med (Maywood)       Date:  2015-11-13

5.  Potential role of zinc in the visceromegaly regression and recovery of hematological parameters during treatment of visceral leishmaniasis in children from an endemic area.

Authors:  Débora Cardozo Bonfim Carbone; Lourdes Zélia Garcia Zanoni; Fernanda Zanoni Cônsolo; Simone Camargo Sanches; Vanessa Quadros Dos Reis; Karla de Toledo Candido Muller; Cristiano Marcelo Espinola Carvalho; Maria Cláudia Silva
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2018-09-13       Impact factor: 1.846

6.  Evaluation of three recombinant proteins for the development of ELISA and immunochromatographic tests for visceral leishmaniasis serodiagnosis.

Authors:  Anna Raquel Ribeiro Dos Santos; Ângela Vieira Serufo; Maria Marta Figueiredo; Lara Carvalho Godoi; Jéssica Gardone Vitório; Andreza Pain Marcelino; Daniel Moreira de Avelar; Fernandes Tenório Gomes Rodrigues; George Luiz Lins Machado-Coelho; Fernanda Alvarenga Cardoso Medeiros; Selma Maria Bezerra Jerônimo; Edward José de Oliveira; Frederico Crepaldi Nascimento; Santuza Maria Ribeiro Teixeira; Ricardo Tostes Gazzinelli; Ronaldo Alves Pinto Nagem; Ana Paula Fernandes
Journal:  Mem Inst Oswaldo Cruz       Date:  2019-02-04       Impact factor: 2.743

7.  Premature deaths by visceral leishmaniasis in Brazil investigated through a cohort study: A challenging opportunity?

Authors:  Ana Nilce S Maia-Elkhoury; Gustavo Adolfo Sierra Romero; Samantha Y O B Valadas; Marcia L Sousa-Gomes; José Angelo Lauletta Lindoso; Elisa Cupolillo; Jose Antonio Ruiz-Postigo; Daniel Argaw; Manuel J Sanchez-Vazquez
Journal:  PLoS Negl Trop Dis       Date:  2019-12-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.